ArticleFrontiers in microbiology2026
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Gut microbiota-host co-metabolism in hypertriglyceridemia-associated acute pancreatitis: from causality to precision intervention.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe acute pancreatitis (SAP) is frequently complicated by intestinal barrier disruption, bacterial translocation, and systemic inflammation. Emerging evidence indicates that gut microbial metabolic disturbances, particularly altered short-chain fatty acids (SCFAs), may contribute to epithelial injury, yet the mechanistic links between microbial metabolites and host inflammatory signaling remain insufficiently defined. We therefore investigated whether Methods: A mouse model of SAP was established and animals received LP18 intervention. Intestinal injury and barrier integrity were evaluated by histopathology, tight junction protein assessment, and inflammatory cytokine measurements. Metabolic alterations were profiled using untargeted metabolomics and targeted quantification of SCFAs was performed. NF-κB signaling was assessed by measuring p65 phosphorylation and nuclear translocation. Correlation analyses were conducted to relate SCFA levels to barrier markers. Results: SAP induced pronounced epithelial injury, including villus atrophy, Tight junction disruption, elevated pro-inflammatory cytokines, and robust NF-κB activation. Untargeted metabolomics revealed extensive metabolic perturbations, with significant changes in butanoate metabolism and lipid-associated pathways. LP18 administration partially reversed these abnormalities and shifted the metabolomic profile toward a mucosa-protective signature. Targeted SCFA analysis showed marked butyrate depletion in SAP mice, whereas LP18 significantly increased butyrate levels and partially normalized acetate and propionate. Higher butyrate concentrations correlated with improved intestinal integrity and reduced inflammatory response. Mechanistically, LP18 suppressed inflammatory signaling by inhibiting p65 phosphorylation and nuclear translocation, consistent with attenuated NF-κB pathway activation. Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.